SCHEMBL2175456

SCHEMBL2175456

O=S(=O)(Cl)c1cc2cccc(OCc3ccccc3)c2s1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 2/20 0.47
MAPT P10636 3/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
MAPK1 P28482 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
MRGPRX4 Q96LA9 2/20 0.40
SMN1; SMN2 Q16637 4/20 0.40
NPC1 O15118 3/20 0.40
RAB9A P51151 3/20 0.40
SRD5A2 P31213 1/20 0.40
HPGD P15428 2/20 0.39
MAOB P27338 1/20 0.39
MEN1 O00255 1/20 0.39
MITF O75030 1/20 0.39
TP53 P04637 1/20 0.39
XBP1 P17861 1/20 0.39
NFKB1 P19838 1/20 0.39
NFKB2 Q00653 1/20 0.39
KMT2A Q03164 1/20 0.39
RELA Q04206 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2173360 0.87 CA2 (0.64) CA2MAPTL3MBTL1MAPK1TDP1
SCHEMBL2175150 0.79 CA2 (0.53) CA2L3MBTL1HPGDLMNANPSR1
SCHEMBL2174657 0.79 CA2 (0.72) CA2SMN1; SMN2NPC1HPGDMEN1
SCHEMBL27254502 0.72 HPGD (0.48) MAPTL3MBTL1MAPK1TDP1MRGPRX4
SCHEMBL1500952 0.70 MAPT (0.50) CA2MAPTL3MBTL1MAPK1TDP1
SCHEMBL2175480 0.70 HDAC3 (0.49) CA2MAPTMAPK1TDP1MEN1
SCHEMBL2176018 0.69 CA2 (0.46) CA2RELA
SCHEMBL2176746 0.68 MAPT (0.51) MAPTL3MBTL1MAPK1TDP1MRGPRX4
SCHEMBL27656865 0.66 FFAR1 (0.49) CA2MAPTL3MBTL1MAPK1TDP1
SCHEMBL3003594 0.66 LTA4H (0.55) MAPTL3MBTL1MAPK1TDP1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7973051-B2 Aminothiazoles as FBPase inhibitors for diabetes HOFFMAN-LA ROCHE INC. (US) 2011-07-05 US disclosed
EP-2227468-A1 AMINOTHIAZOLE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2010-09-15 EP disclosed
US-20090143448-A1 NEW AMINOTHIAZOLES AS FBPASE INHIBITORS FOR DIABETES F. HOFFMANN-LA ROCHE AG (CH) 2009-06-04 US disclosed
WO-2009068467-A1 AMINOTHIAZOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-06-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143448-A1 NEW AMINOTHIAZOLES AS FBPASE INHIBITORS FOR DIABETES FBP1, SLC5A1, DPP4 CA2 1616/4885MAPT 1274/4885L3MBTL1 3174/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.